A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors
Authors:
Open Access
- 2 April 2012
- journal article
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 19 (5) , 522-528
Abstract
Conventional prothrombin time (PT) assays have limited sensitivity and dynamic range in monitoring the anticoagulant activity of direct factor Xa inhibitors. Hence, new assays are needed. We modified a PT assay by adding calcium chloride (CaCl2) to the thromboplastin reagent to increase assay dynamic range and improve sensitivity. Effects of calcium and sodium ion concentrations, and sample handling, were evaluated to optimize assay performance. Increasing concentrations of calcium ions produced progressive increases in PT across the factor Xa inhibitor concentrations of 0 to 2500 nmol/L for razaxaban and apixaban. The greatest effect was seen when the thromboplastin reagent was diluted 1:2.25 with 100 mmol/L CaCl2 (thus selected for routine use). The optimized assay showed an interassay precision of 1.5 to 9.3 percentage coefficient of variation (%CV) for razaxaban and 3.1 to 4.6 %CV for apixaban. We conclude that the modified PT assay is likely to be suitable as a pharmacodynamic marker for activity at therapeutic concentrations of factor Xa inhibitors.Keywords
This publication has 15 references indexed in Scilit:
- Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assayThrombosis and Haemostasis, 2010
- Rivaroxaban, an oral direct factor Xa inhibitorExpert Opinion on Investigational Drugs, 2008
- Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studiesJournal of Thrombosis and Haemostasis, 2008
- Current and Future Prospects for Anticoagulant Therapy: Inhibitors of Factor Xa and Factor IIaSeminars in Thrombosis and Hemostasis, 2008
- ApixabanDrugs of the Future, 2008
- SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infectionBlood, 2007
- Fit-for-Purpose Method Development and Validation for Successful Biomarker MeasurementPharmaceutical Research, 2006
- Oral Anticoagulants in DevelopmentDrugs, 2006
- Inhibition of Factor XaAmerican Journal of Cardiovascular Drugs, 2005
- American Heart Association/American College of Cardiology Foundation Guide to Warfarin TherapyCirculation, 2003